How does CPHG.F's PE Ratio compare to its peers?

CPHG.F is good value based on its Price-To-Earnings Ratio (7.2x) compared to the peer average (20.8x).

How does CPHG.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

CPHG.F is good value based on its Price-To-Earnings Ratio (7.2x) compared to the US Pharmaceuticals industry average (16.7x).

What is CPHG.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CPHG.F's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of CPHG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CPHG.F ($1.04) is trading below our estimate of [[fair value]] ($2.57)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

CPHG.F Stock Overview

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. More details

CPHG.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	4/6
Financial Health	6/6
Dividends	5/6

Rewards

Trading at 59.4% below our estimate of its fair value

Earnings are forecast to grow 14.72% per year

Earnings have grown 25.8% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Unstable dividend track record

My Notes

Capture your thoughts, links and company narrative

Consun Pharmaceutical Group Limited Competitors

Phibro Animal Health

NasdaqGM:PAHC

US$878.5m

Collegium Pharmaceutical

NasdaqGS:COLL

US$957.8m

SIGA Technologies

NasdaqGM:SIGA

US$422.0m

Innoviva

NasdaqGS:INVA

US$1.1b

Price History & Performance

Summary of share price highs, lows and changes for Consun Pharmaceutical Group
Historical stock prices
Current Share Price	HK$1.04
52 Week High	HK$1.04
52 Week Low	HK$1.04
Beta	0.54
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CPHG.F	US Pharmaceuticals	US Market
7D	0%	1.6%	-2.2%
1Y	n/a	9.7%	23.9%

Return vs Industry: Insufficient data to determine how CPHG.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CPHG.F performed against the US Market.

Price Volatility

Is CPHG.F's price volatile compared to industry and market?
CPHG.F volatility
CPHG.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CPHG.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CPHG.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	3,178	Meng An	www.chinaconsun.com

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products.

Consun Pharmaceutical Group Limited Fundamentals Summary

How do Consun Pharmaceutical Group's earnings and revenue compare to its market cap?
CPHG.F fundamental statistics
Market cap	US$822.63m
Earnings (TTM)	US$114.63m
Revenue (TTM)	US$375.37m

7.2x

P/E Ratio

2.2x

P/S Ratio

Is CPHG.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CPHG.F income statement (TTM)
Revenue	CN¥2.74b
Cost of Revenue	CN¥706.20m
Gross Profit	CN¥2.03b
Other Expenses	CN¥1.20b
Earnings	CN¥836.41m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.01
Gross Margin	74.22%
Net Profit Margin	30.54%
Debt/Equity Ratio	12.7%

How did CPHG.F perform over the long term?

See historical performance and comparison

Dividends

7.4%

Current Dividend Yield

52%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 15:56
End of Day Share Price	2024/12/10 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Consun Pharmaceutical Group Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Fangqi Dai	China Merchants Securities (HK) Co., Ltd
null null	CMB International Securities Limited
Trina Chen	Credit Suisse